Paul Oberstein, MD
Perlmutter New York University Cancer Center · NYU Langone Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul Oberstein, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:52 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05984602 · A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic CancerNYU Langone Health · active not recruiting · Pancreatic Cancer · principal investigator
- N/ANCT05483075 · Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic CancerNYU Langone Health · completed · Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.